The First Flight Venture Center (FFVC) has been selected as a winner for the Small Business Association’s (SBA) Growth Accelerator Fund Competition. This funding will support FFVC’s “LiftOff” program, in which early stage science companies will receive expert mentorship and support to submit high-quality grant applications. The LiftOff program employs a unique model in which Eva […]
EGC was selected to lead the grant fundraising efforts for First Flight Venture Center (FFVC) in Research Triangle Park, NC. FFVC is a technology incubator established in 1991 to support early stage companies with high-impact science that contribute to the economic development of North Carolina. In her role as Director of Development at FFVC, Dr. Garland will assist FFVC in obtaining […]
EGC congratulates client Agile Sciences on their $1.5M Phase II NIH SBIR Award. The funding will support pre-clinical development of Agile Sciences’ novel approach to treating chronic wounds.
EGC was pleased to sponsor the NIH SBIR/STTR National Conference in Albuquerque, New Mexico. The annual conference attracts many of the most innovative health entrepreneurs in the nation, and this year’s conference featured a special “Pitch Fiesta” highlighting companies who have received SBIR/STTR awards. EGC assists these innovative entrepreneurs in incorporating grant funding into their development […]
On October 8, 2014, Dr. Eva Garland served as a panelist for the Forum, “Let’s Talk About Bootstrapping for Life Sciences”. The Forum was hosted by Scale Finance and First Flight Venture Center. Link to more information.
Dr. Eva Garland appeared as a guest on radio station WCOM’s “Focus on Business” show. Dr. Garland discussed funding strategies for advancing research and development of innovative technologies. The show aired live on Tuesday, April 29 from noon – 1 PM. Link to podcast.
GO2, LLC, a client of Eva Garland Consulting, has developed a highly innovative treadling device called the CV2. GO2 worked with EGC to submit a NIH SBIR proposal to conduct clinical trials that are expected to further demonstrate the substantial benefits of the CV2 for addressing complications of diabetes.
Dr. Eva Garland presented a seminar entitled, “Using Non-Dilutive Funding to Advance Technology Development” at First Flight Ventures at 12 PM on Wednesday, March 12.